(TXMD) – FDA Approves TherapeuticsMD’s Low Dose Bijuva


TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.



Source link

Leave a Reply

Your email address will not be published.

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...